Abstract
Growth hormone (GH) is a potent stimulator of insulin-like growth factor- 1 (IGF-1), which in its turn has been proven to stimulate both cell proliferation and protein synthesis in various systems. Thus, the question may be raised whether the therapeutic use of GH, particularly in transplant patients, may increase the risk of developing malignant tumors or causing recurrence of a previous tumor that is thought to be under control [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ritzén EM. Does growth hormone increase the risk of malignancies? Horm Res 1993; 39: 99–101.
Zadik Z, Estrov Z, Karov Y, Hahn T, Barak Y. The effect of growth hormone and IGF-1 on clonogenic growth of hematopoietic cells in leukemic patients during active disease and durning remission — A preliminary report. J Pediatr Endocrinol 1993; 6: 79–83.
Ogilvy-Stuart AL, Shalet SM. Tumour occurrence and recurrence. Horm Res 1992; 38 (suppl 1): 50–55.
Wilton R Adverse effect during growth hormone treatment: 5 years’ experience in the Kabi International Growth Study. In: Ranke MB, Gunnarsson R, editors. Progress in Growth Hormone Therapy — 5 years of the KIGS. Mannheim, Germany: J & J Verlag, 1994: 291–307.
Stahnke N. Leukemia in growth-hormone-treated patients: an update, 1992. Horm Res 1992; 38 (suppl 1): 56–62.
Butturini A, Bernasconi S, Izzi G, Gertner JM, Gale RP. Short stature, Fanconi’s anemia, and risk of leukaemia after growth hormone therapy. Lancet 1994; 343: 1576.
Watanabe S, Mizuno S, Oshima LH, Tsunematsu Y, Fujimoto J, Komiyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol 1993; 6: 99–108.
Momoi T, Yamanaka C, Yorifuji T et al. Wilms tumour in a patient with growth hormone replacement therapy. Eur J Pediatr 1989; 149: 159–161.
Bourguignon JP, Pierard E, Ernould C et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993; 341: 1505–1506.
Petersen BH, Rapaport R, Henry DP, Huseman C, Moore WV. Effect of treatment with biosynthetic human growth hormone on peripheral blood lymphocyte populations and function in growth hormone-deficient children. J Clin Endocrinol Metab 1990; 70: 1756–1760.
Tönshoff B, Haffner D, Mehls O et al. Efficacy and safety of growth hormone treatment in short children with renal allografts: three year experience. Kidney Int 1993; 44:199–207.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Cochat, P., Saïd, MH., Lesage, C., Gouffrant, C., Berlier, P. (1996). Risk of cancer in transplant patients treated with recombinant growth hormone. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Cancer in Transplantation: Prevention and Treatment. Transplantation and Clinical Immunology, vol 27. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0175-9_15
Download citation
DOI: https://doi.org/10.1007/978-94-009-0175-9_15
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6563-4
Online ISBN: 978-94-009-0175-9
eBook Packages: Springer Book Archive